Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Oncorus, Inc.
  6. News
  7. Summary
    ONCR   US68236R1032

ONCORUS, INC.

(ONCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ONCORUS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

11/19/2021 | 04:49pm EST

Item 1.01 Entry into a Material Definitive Agreement.

On November 19, 2021, Oncorus, Inc. (the "Company") entered into an Open Market Sale AgreementSM (the "Sale Agreement") with Jefferies LLC, as sales agent ("Jefferies"), pursuant to which the Company may issue and sell shares of its common stock, par value $0.0001 per share (the "Common Stock"), from time to time for an aggregate sales price of up to $50 million through Jefferies.

Sales of the Common Stock, if any, under the Sale Agreement will be made by any method that is deemed to be an "at the market offering" as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including, but not limited to, sales made directly on or through The Nasdaq Global Market or any other existing trading market for the Common Stock. The Company has no obligation to sell any of the Common Stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. The offering of shares of Common Stock pursuant to the Sale Agreement will terminate upon the earlier of (i) the sale of all Common Stock subject to the Sale Agreement or (ii) termination of the Sale Agreement in accordance with its terms.

Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell the Common Stock from time to time, as the sales agent, based upon the Company's instructions.

The Company has provided customary representations, warranties and covenants, and the parties have agreed to indemnification rights. Jefferies will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds for each sale of the Common Stock.

This description of the Sale Agreement does not purport to be complete and is qualified in its entirety by reference to the terms of the Sale Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The Common Stock to be sold under the Sale Agreement, if any, will be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-260718), filed with the Securities and Exchange Commission ("SEC") on November 3, 2021, which was declared effective on November 12, 2021. On November 19, 2021, the Company filed a prospectus supplement with the SEC in connection with the offer and sale of the Common Stock pursuant to the Sale Agreement. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock nor shall there be any sale of the Common Stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

The legal opinion of Cooley LLP relating to the legality of the issuance and sale of the Common Stock is attached as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated by reference herein. Certain information relating to Part II, Item 14 of the above referenced registration statement under the heading "Other Expenses of Issuance and Distribution" with respect to the sale of Common Stock under the Sale Agreement is being filed as Exhibit 99.1 to this Current Report on Form 8-K to be incorporated by reference into such registration statement.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.       Description

5.1                 Legal Opinion of Cooley LLP

10.1                Open Market Sale AgreementSM dated November 19, 2021, by and
                  between Oncorus, Inc. and Jefferies LLC

23.1                Consent of Cooley LLP (included in Exhibit 5.1)

99.1                Information related to Item 14 of the Registration Statement
                  on Form S-3 (333-260718)

104               Cover Page Interactive Data File (embedded within the inline
                  XBRL document)





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ONCORUS, INC.
01/10ONCORUS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/03Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference
AQ
2021ONCORUS, INC.(NASDAQGM : ONCR) added to NASDAQ Biotechnology Index
CI
2021Oncorus to Present at Upcoming Investor Conferences
GL
2021ONCORUS : Information related to Item 14 of the Registration Statement on Form S-3 (333-26..
PU
2021ONCORUS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhib..
AQ
2021Oncorus to Present at the Jefferies London Healthcare Conference
AQ
2021Oncorus Says Initial Data on ONCR-177 Show Clinical Benefit for Three Out of Eight Pati..
MT
2021Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical R..
PU
2021ONCORUS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Othe..
AQ
More news
Analyst Recommendations on ONCORUS, INC.
More recommendations